20269月
BMY Sep 2026 · Sell
We rate Bristol-Myers Squibb a Sell with a Fair value of USD 42.47, representing 31.4% downside from the USD 61.94 price on September 25, 2026, as impending patent losses on core blockbusters outweigh commercial growth portfolio contributions.Latest published research · analyzed 2026-09-25 · current · sources stale